DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TREATMENTS
       *****************************************************
       #Post#: 3620--------------------------------------------------
       Long-term treatment w/anti-CD20 monoclonal antibodies untenable 
       because of risk?
       By: agate Date: April 21, 2022, 1:32 am
       ---------------------------------------------------------
       Multiple Sclerosis Journal routinely publishes a "Controversies
       in MS" section, where one side of a controversial topic is
       presented, followed by the opposing view, and concluding with a
       comment on both presentations. This time there is only the "Yes"
       side of the controversy, in an article entitled "Long-term
       treatment with anti-CD20 monoclonal antibodies is untenable
       because of risk: YES" (April 18, 2022). This is a PDF file:
  HTML https://bit.ly/3vBeriH
       The drugs that are anti-CD20 monoclonal antibodies are
       ocrelizumab (Ocrevus),  ofatumumab (Kesimpta),  and the
       off-label-use drug rituximab (Rituxan)
       #Post#: 3679--------------------------------------------------
       Commentary on riskiness of long-term treatment w/anti-CD20 monoc
       lonal antibodies
       By: agate Date: June 10, 2022, 1:32 am
       ---------------------------------------------------------
       The latest issue of Multiple Sclerosis Journal (June 9, 2022)has
       reprinted the article cited above as well as the "No" side of
       the debate, and both are summarized in the attached
       "Commentary":
  HTML https://journals.sagepub.com/doi/full/10.1177/13524585221101138
       *****************************************************